Sihuan Pharma Subsidiary Xuanzhu's Bireociclib Gains China Reimbursement for First-Line Breast Cancer TreatmentPUBT·Nov 16, 2026 at 08:40 AM02575-3.37%004600.00%
Xuanzhu Biopharmaceutical’s New Bireociclib Indication Included in China’s 2026 NRDLTip Ranks·Nov 15, 2026 at 10:38 AM02575-3.37%
Weekly Recap | XUANZHUBIO-B +8.28%, record low then reboundWeekly Review·Nov 7, 2026 at 05:52 AM02575-3.37%
XuanzhuBio climbs 6% as Phase III anaprazole data shows efficacyMarket Movers·Nov 5, 2026 at 03:13 AM02575-3.37%
Xuanzhu Biopharmaceutical’s Anaprazole Sodium Meets Primary Endpoint in Phase III Reflux Esophagitis TrialPUBT·Oct 21, 2026 at 12:54 PM02575-3.37%
One Insurance Table, Nine Stories: How Hong Kong's Orphan Small Caps Price ThemselvesGlobal Report·Oct 21, 2026 at 10:52 AM02126-5.01%02575-3.37%
Small-Cap AI Gambits Reshape Hong Kong's Niche MarketsGlobal Report·Oct 21, 2026 at 09:18 AM03680-0.67%01732-0.52%
Weekly Recap | XUANZHUBIO-B -1.9%, small-cap moves stay name-by-nameWeekly Review·Oct 17, 2026 at 05:46 AM02575-3.37%
Hong Kong Small Caps Are Moving One Company at a TimeGlobal Report·Oct 13, 2026 at 10:51 AM01779-7.99%02575-3.37%
Hong Kong's 'New Energy' Tech List Mixes Coconut Water and Beer as 6106 Emerges SoloGlobal Report·Oct 13, 2026 at 09:24 AM06603+0.33%06106-0.92%
Weekly Recap | XUANZHUBIO-B -2.33%, an up-and-down weekWeekly Review·Oct 10, 2026 at 05:25 AM02575-3.37%
Execution Over Hype: Biotech Data Waves and Power Plant Milestones Reshape Hong KongGlobal Report·Oct 6, 2026 at 09:17 AM00168+0.19%00991+1.20%